Future Fertility today announced that Christine Prada has been named as Chief Executive Officer. Her employment with Future Fertility will commence in early May.
Future Fertility, a fertility technology company developing AI-enabled and non-invasive solutions to optimize clinical decision making for fertility specialists, today announced that Christine Prada has been named as Chief Executive Officer. Her employment with Future Fertility will commence in early May. Prada joins Future Fertility as a tenured executive in the healthcare and healthcare technology industry with a strong reputation as a versatile, results-focused leader with a growth mindset. Prada spent the past five years building and leading business development at Maple Corporation, a leading Canadian virtual care company. Prada joined as Maple’s third employee, and built, scaled, and accelerated the growth of Maple’s corporate and public sector businesses, which eventually helped the company to raise a CAD$75M investment by Shoppers Drug Mart. Prior to Maple, Prada worked in KPMG’s health and life science commercial strategy practice, providing strategic advice and leading the execution of critical health transformation projects for key government and private sector clients.
Prada succeeds Diana Olusanmi, a well-respected technology industry leader who has served Future Fertility as CEO over the past two years. Olusanmi is an early investor in Future Fertility and took on the role of CEO in early 2020. She was instrumental in bringing the company’s first product – Violet™, a non-invasive tool that assesses viability of eggs for fertilization – to market. Olusanmi has also been crucial in raising funding for the business, most recently working to secure a US$6M investment round led by Whitecap Venture Partners and M Ventures. She also built the foundation for a strong operational structure to drive global growth.
“On behalf of the whole team, I want to thank Diana for being an advisor to the company since its beginnings and her leadership as CEO,” said Dr. Dan Nayot, co-founder and CMO at Future Fertility. “The strong foundation Diana and team have put in place sets Future Fertility up for an exciting next stage of growth. We are very grateful to her for stepping in at a crucial time and thank her for her service.”
“Christy’s experience building sales teams and partnerships in the healthcare technology space is exactly what we need to help take this business to the next level. I feel excited and reassured to pass on the leadership of Future Fertility to Christy’s capable hands,” said Olusanmi.
“I am thrilled to be joining Future Fertility at such a pivotal time and look forward to helping the team take the product to the next level of growth globally,” said Prada. “With a success rate of only around 30%, the IVF process is ripe for innovation and provides a perfect opportunity for AI tools to improve outcomes. Dr. Dan Nayot, Alex Krivoi, and the whole Future Fertility team have uncovered an important niche in the process, filling a critical gap in a fast-growing global market. I believe Future Fertility’s technology has the power to help millions of families around the world improve their chances of successful reproduction, reducing emotional and financial stress through the process.”
Prada holds a BMOS Degree from the University of Western Ontario, and an MBA from the University of Toronto’s Rotman School of Management. She is also an active proponent of female entrepreneurship, investing in early-stage, women-led/backed companies via her role as a General Partner at the Women’s Equity Lab.
About Future Fertility
Future Fertility is an innovation-focused fertility technology company developing non-invasive AI-enabled fertility solutions to improve clinical decision making in fertility care and in vitro fertilization (IVF). Our mission is to harness the power of AI to improve fertility care and IVF outcomes, lower costs, and alleviate emotional stress of the patient journey. We’ve developed the first Artificial Intelligence image analysis tool to non-invasively evaluate oocytes (eggs), creating the only objective classification and prediction tool, Violet™, for an oocyte. Beyond our flagship egg prediction software product, Future Fertility has additional AI solutions in its pipeline, unlocking key decision points in IVF cycles. For additional information, visit futurefertility.com.
